Evaluating taletrectinib in the treatment of patients with ROS1 fusion-positive non–small cell lung cancer
4 affiliations
- 1Department of Medicine, University of California Irvine School of Medicine, Orange, CA, USA
- 2Department of Medicine, St. Marianna University School of Medicine, Kawasaki, Japan
- 3University of California Irvine School of Medicine, Orange, CA, USA
- 4Corona Del Mar High School, Newport Beach, CA, USA
Abstract
ROS1 fusion-positive non–small cell lung cancer (NSCLC), occurring in 1–2% of patients, represents a rare but clinically important subset. Patients with ROS1 fusion-positive NSCLC are often younger and tend to have little or no history of smoking. Current first-generation tyrosine kinase inhibitors (TKIs) such as crizotinib and entrectinib provide meaningful benefit but are limited by poor central nervous system (CNS) penetration and the development of resistance mutations, particularly G2032R. To overcome the challenges of first‑generation ROS1 inhibitors, next‑generation ROS1 inhibitors have been developed. Repotrectinib was evaluated earlier, and taletrectinib followed. Both are considered next‑generation ROS1 inhibitors with excellent CNS penetration and the ability to tackle resistance mutations such as G2032R, and they have been FDA approved. While both drugs, repotrectinib and taletrectinib, provide impressive results regarding overall and intracranial efficacy, as well as responses seen even in the presence of the resistant G2032R mutation, their toxicity profiles appear different. Repotrectinib appears to have a higher incidence of neurological toxicities, whereas taletrectinib has a higher incidence of gastrointestinal toxicities. Zidesamtinib has recently been approved in the pre-treated population, and taletrectinib is also being evaluated in the adjuvant setting.
Related
- Probable Stevens–Johnson Syndrome During Taletrectinib Treatment After Crizotinib‐Related Rash in ROS1‐Positive Lung Cancer
- Salivary gland dynamic imaging combined with tomosynthesis fusion imaging for evaluating postoperative salivary gland function changes in patients with differentiated thyroid cancer undergoing initial 131I therapy
- Evaluating Darbepoetin Treatment Strategies for Managing Anaemia in Haemodialysis Patients: Effects on All-Cause Mortality From a Target Trial Emulation Using Electronic Health Record Data.
- Quality of life in patients with systemic lupus erythematosus: positive associations with younger age, higher education, low disease activity, and corticosteroid and cyclophosphamide treatment—cross-sectional study in northwestern Poland
- Implementing a medical opinion leader-led management model to promote timely treatment initiation among screen-positive patients with upper gastrointestinal cancer in rural China: a cluster randomised controlled trial protocol
BibTeX
@article{nagasaka2026evaluating,
title = {{Evaluating taletrectinib in the treatment of patients with ROS1 fusion-positive non–small cell lung cancer}},
author = {Misako Nagasaka and Cathleen J. Park and Zhaohui L. Arter and Torrance Teng and Jacob Lee and Rozhan Ziari and Ravand Samaeekia and Sai-Hong Ignatius Ou},
journal = {Future Oncology},
year = {2026},
month = oct,
doi = {10.1080/14796694.2026.2740954},
url = {https://doi.org/10.1080/14796694.2026.2740954},
note = {CC BY-NC-ND 4.0},
}
RIS
TY - JOUR
TI - Evaluating taletrectinib in the treatment of patients with ROS1 fusion-positive non–small cell lung cancer
AU - Misako Nagasaka
AU - Cathleen J. Park
AU - Zhaohui L. Arter
AU - Torrance Teng
AU - Jacob Lee
AU - Rozhan Ziari
AU - Ravand Samaeekia
AU - Sai-Hong Ignatius Ou
PY - 2026
DA - 2026/10/08
JO - Future Oncology
DO - 10.1080/14796694.2026.2740954
UR - https://doi.org/10.1080/14796694.2026.2740954
AB - ROS1 fusion-positive non–small cell lung cancer (NSCLC), occurring in 1–2% of patients, represents a rare but clinically important subset. Patients with ROS1 fusion-positive NSCLC are often younger and tend to have little or no history of smoking. Current first-generation tyrosine kinase inhibitors (TKIs) such as crizotinib and entrectinib provide meaningful benefit but are limited by poor central nervous system (CNS) penetration and the development of resistance mutations, particularly G2032R. To overcome the challenges of first‑generation ROS1 inhibitors, next‑generation ROS1 inhibitors have been developed. Repotrectinib was evaluated earlier, and taletrectinib followed. Both are considered next‑generation ROS1 inhibitors with excellent CNS penetration and the ability to tackle resistance mutations such as G2032R, and they have been FDA approved. While both drugs, repotrectinib and taletrectinib, provide impressive results regarding overall and intracranial efficacy, as well as responses seen even in the presence of the resistant G2032R mutation, their toxicity profiles appear different. Repotrectinib appears to have a higher incidence of neurological toxicities, whereas taletrectinib has a higher incidence of gastrointestinal toxicities. Zidesamtinib has recently been approved in the pre-treated population, and taletrectinib is also being evaluated in the adjuvant setting.
SN - 1479-6694
SN - 1744-8301
ER -